October 2026 FDA Update: BD Alaris Infusion Set Class I Recall — Low-Flow Accuracy Overstated and Certain Sets Must Be Removed from Use

October 2026 FDA Update: BD Alaris Infusion Set Class I Recall

On October 5, 2026, the U.S. Food and Drug Administration (FDA) updated its communication on the Class I recall of BD and CareFusion Alaris infusion pump sets. The update adds affected products and replaces performance data previously provided by the company in 2025 field action MMS-25-5311. FDA states that certain sets with closed male luer connectors, filters, check valves, Y-sites or microbore tubing perform below previously published accuracy, with deviations concentrated at flow rates below 1 mL/h and bolus volumes of 5 mL or less. These deviations may cause under-infusion or over-infusion, delayed occlusion alarms and inaccurate bolus doses. The company requires affected sets to be identified and discarded, with replacement supply prioritized for critical care, neonatal, infant and pediatric units, and syringe pumps used where necessary with enhanced clinical monitoring.

What changed in this update

On October 5, 2026, FDA updated its communication page on the BD Alaris infusion pump set recall. The update contains two main changes: additional affected products were brought into scope, and new performance data replaced the earlier data provided by the company in 2025 field action MMS-25-5311. FDA explicitly states that this action is a Class I recall, the most serious category. According to the timeline on the page, this classification has been effective since September 29, 2025, and the earliest safety communication dates back to an early alert issued on July 15, 2025.

In FDA's recall database, the corresponding record is recall number Z-3080-2026, event ID 99298, with BD Switzerland SARL as the recalling firm and an FDA posting date of September 15, 2026. Therefore, October 5 is a further update of the communication page, not the launch of an entirely new recall. This distinction is important for company response planning: the list is changing and the handling requirements are also changing, so actions should not be based only on the first announcement.

Affected products

The products named are Alaris infusion pump sets used with the BD Alaris Pump Module 8100, with software scope covering Guardrails Suite MX 12.6 and earlier versions. FDA provides a download link for the complete affected product list on the page and separately identifies discontinued sets in Appendix C of the company customer letter. The company issued an updated letter to affected customers on August 19, 2026.

Two levels need to be distinguished: first, the pump module and software version; second, the specific infusion set part numbers used with that module. FDA's handling requirements mainly apply to the latter, namely identifying and discarding sets listed on the discontinued list. For hospitals, the focus should be on consumable inventory and the specific part numbers in use. Equipment asset records will not be sufficient for this purpose.

Performance claims versus actual performance

According to BD, some Alaris pump sets are structurally limited and perform worse in actual use than previously disclosed. Such structures include closed male luer connectors, filters, check valves, Y-sites and microbore tubing. Following continued testing, the company confirmed that earlier claimed performance was overstated, with significant differences in some cases.

Deviations most commonly occur in two scenarios: programmable flow rates below 1 mL/h and bolus volumes of 5 mL or less. The corresponding consequences are greater degrees of under-infusion or over-infusion, delayed occlusion alarm times and inaccurate bolus doses. These deviations are not easy for users to identify immediately and are therefore difficult to link causally to changes in a patient's condition at the first opportunity.

Why high-risk populations are more affected

FDA identifies three patient groups in its explanation: neonates, pediatric patients and critically ill patients. The reason is straightforward: these patients are more likely to receive low-flow, small-volume infusions, such as antiarrhythmic agents or vasopressors. The same dose deviation can have amplified consequences in these patients.

FDA also states that, as of August 19, 2026, BD had not reported serious injury or death related to this issue. This statement should be read literally: it reflects the current status under the company's reporting, and does not mean the risk has been excluded. The Class I classification itself indicates that FDA considers continued use potentially capable of causing serious injury or death.

Required actions specified by FDA

The handling sequence is set out specifically on the page.

• First, immediately identify and discard the discontinued sets listed in Appendix C in accordance with institutional procedures.
• Second, select another clinically appropriate Alaris set for the corresponding clinical use.
• Third, if replacement sets are limited in supply, prioritize critical care, neonatal, infant and pediatric units.

If the available set combination is no longer clinically appropriate, another pump should be used, such as the Alaris syringe pump module or another syringe pump. Only when syringe pumps are also unavailable may recalled sets be used cautiously with enhanced clinical monitoring and compliance with existing warnings. Appendix D of the company customer letter lists system labeling warnings.

Risk mitigation instructions

The page also lists several risk mitigation actions:

• Do not hang solution containers below the pump module, and do not position them more than 21 inches above the top of the pump module.
• When loading the set, ensure that the tubing is properly aligned with the pressure sensor.
• Confirm that all clamps are open, that there are no kinks or flattening outside the tubing, that drops are falling in the drip chamber, and that vents are open if necessary.
• For flow rates below 10 mL/h, do not use the optional pressure mode set above 50 mmHg.
• When managing an occlusion, first ensure that fluid flow to the patient is closed; if a stopcock is available, disconnect the set to relieve pressure, while weighing the risk of disconnection against the risk of inadvertent bolus delivery.

Implications for registration and supply

This type of issue has not been isolated over the past year. Infusion sets are consumables with highly customized combinations of structure and materials, and a single pump platform can generate a large number of part numbers. Performance validation often covers representative configurations and cannot readily cover every combination. Once a systematic deviation arises between claimed and actual values, an entire product line may be affected; a single model is the exception rather than the rule.

FDA's communication approach is also noteworthy: an early alert first, then classification, followed by multiple scope expansions and data replacements. This means companies need to continuously track page updates during a recall cycle and should not treat the first announcement's list as the end point. For manufacturers supplying multiple markets, a data correction in one market often affects labels, instructions for use and distributor inventory in other markets.

Sources and verification scope

• U.S. Food and Drug Administration (FDA): Infusion Set Recall: BD and CareFusion 303, Inc. Remove BD Alaris Pump Infusion Sets, updated October 5, 2026. https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/infusion-set-recall-bd-and-carefusion-303-inc-remove-bd-alaris-pump-infusion-sets
• FDA Medical Device Recall Database: Recall number Z-3080-2026, event ID 99298, posted September 15, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?start_search=1&event_id=99298

Verification was performed on October 17, 2026. The full text of the FDA recall communication page, the timeline on the page, the affected products and handling requirements, and the record fields for Z-3080-2026 in FDA's recall database (recalling firm, posting date and event ID) were checked. The specific part numbers in the company customer letter and its appendix lists were not verified, and no check was made as to whether other regulatory authorities have issued corresponding actions.

This article is an interpretation of publicly available information from a U.S. regulatory authority and does not constitute a conclusion or commitment regarding any specific product, company or registration application. The recall scope, classification and handling requirements are subject to the original FDA text and the company customer letter, and the relevant information may change with subsequent official updates. Clinical operational recommendations mentioned in this article should be subject to the procedures of the institution concerned and the product instructions for use.

AIMEILI Regulatory Interpretation

This update illustrates a key regulatory characteristic of infusion set recalls: the scope of a Class I action can expand after the initial notification, and the performance data underlying the recall can be replaced during the recall cycle. For regulatory affairs teams, the October 5, 2026 update should not be treated as a routine page revision. It changes both the affected product population and the technical basis for risk assessment. Companies that supply Alaris-compatible sets, or that reference similar performance claims in their own technical files, should reassess whether their claimed low-flow accuracy and bolus accuracy are supported by validation data covering the specific set configurations in scope, including closed male luer connectors, filters, check valves, Y-sites and microbore tubing.

From a market access and post-market perspective, FDA's action also signals that low-flow performance below 1 mL/h and small-volume boluses of 5 mL or less are becoming a heightened scrutiny area. Manufacturers should review instructions for use, labeling and risk management files to ensure that performance claims are consistent with the validated configurations and that residual risks are communicated clearly. Where multiple regulatory jurisdictions are involved, a U.S. data correction may trigger assessment obligations under other markets' change notification, field safety corrective action and labeling requirements. A coordinated regulatory impact assessment is advisable rather than handling the U.S. action in isolation.

Business Impact

For manufacturers and distributors, the immediate business impact is supply allocation and inventory control. Discontinued sets must be segregated and removed from saleable or usable stock, while replacement sets need to be prioritized for critical care, neonatal, infant and pediatric units. Distributors should reconcile affected part numbers against customer inventories and open orders, and should prepare clear customer communications that distinguish between pump module/software scope and specific set part numbers.

For CROs and regulatory affairs teams supporting infusion pump or infusion set developers, the update reinforces the need for configuration-specific validation and robust change control. Performance claims should be traceable to test configurations that reflect real clinical use, especially for low-flow and small-volume delivery. Companies should also maintain a recall-response process that can accommodate multiple scope expansions and data replacements, including rapid updates to customer letters, labeling, distributor instructions and regulatory notifications in other markets.